Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
NCT02658968
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed, Diffuse Large B-cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Interventions
DRUG:
Betalutin
Sponsor
Nordic Nanovector